iCure-AML

Acute myeloid leukemia (AML) and high-risk myelodysplastic neoplasia (hrMDS) are aggressive hematologic malignancies with a particular poor prognosis. We hypothesize that our Sleeping Beauty Adaptor-FITC (SB Ad-FITC) CAR T-cell platform coupled with anti-CD117 binders can facilitate the academic translation of innovative approaches to eradicate AML/hrMDS cells and, concomitantly, serve as a non-cytotoxic conditioning before allogeneic hematopoietic stem cell transplantation. This will in best case fundamentally change current clinical practice and improve outcomes, first in patients with AML/hrMDS relapse after allogeneic hematopoietic stem cell transplantation, and subsequently in patients at earlier treatment stages with acceptable toxicity. Finally, we envision establishing a pipeline for the discovery of further highly effective target binders that can be coupled with our sleeping beauty adaptor CAR T-cells.